Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amir R Aref

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Cancer Discovery|April 15, 2017
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung CancerDennis O Adeegbe, Yan Liu, Patrick H Lizotte, et al.
Cancer Cell|December 10, 2014
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitorCamilla L Christensen, Nicholas Kwiatkowski, Brian J Abraham, et al.
Cancer Discovery|January 22, 2014
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuitZehua Zhu, Amir R Aref, Travis J Cohoon, et al.
Cancer Research|February 3, 2016
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor MicroenvironmentShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Neuro-Oncology|June 28, 2025
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cellsRishab Ramapriyan, Fred G Barker, Leland G Richardson, et al.
Cell|November 3, 2018
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaMoshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.
Cell|January 12, 2019
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaMoshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.
Cancer Discovery|November 5, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S Wang, Russell W Jenkins, et al.
Nature|January 12, 2023
Targeting TBK1 to overcome resistance to cancer immunotherapyYi Sun, Or-Yam Revach, Seth Anderson, et al.
Cancer Discovery|November 5, 2017
<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor SpheroidsRussell W Jenkins, Amir R Aref, Patrick H Lizotte, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cancer Discovery|April 15, 2017
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung CancerDennis O Adeegbe, Yan Liu, Patrick H Lizotte, et al.
Cancer Cell|December 10, 2014
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitorCamilla L Christensen, Nicholas Kwiatkowski, Brian J Abraham, et al.
Cancer Discovery|January 22, 2014
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuitZehua Zhu, Amir R Aref, Travis J Cohoon, et al.
Cancer Research|February 3, 2016
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor MicroenvironmentShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Neuro-Oncology|June 28, 2025
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cellsRishab Ramapriyan, Fred G Barker, Leland G Richardson, et al.
Cell|November 3, 2018
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaMoshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.
Cell|January 12, 2019
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaMoshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.
Cancer Discovery|November 5, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S Wang, Russell W Jenkins, et al.
Nature|January 12, 2023
Targeting TBK1 to overcome resistance to cancer immunotherapyYi Sun, Or-Yam Revach, Seth Anderson, et al.
Cancer Discovery|November 5, 2017
<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor SpheroidsRussell W Jenkins, Amir R Aref, Patrick H Lizotte, et al.
Pageof 3